Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 4,180,000 shares, a drop of 7.7% from the September 30th total of 4,530,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 3.4 days. Currently, 3.5% of the shares of the stock are sold short.
Amneal Pharmaceuticals Stock Up 0.2 %
AMRX stock opened at $8.57 on Thursday. Amneal Pharmaceuticals has a twelve month low of $3.72 and a twelve month high of $8.95. The company has a market cap of $2.65 billion, a P/E ratio of -15.30 and a beta of 1.18. The business’s fifty day moving average is $8.53 and its 200-day moving average is $7.40.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The firm had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Research analysts anticipate that Amneal Pharmaceuticals will post 0.52 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on AMRX
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals during the second quarter worth $26,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter worth $42,000. Atlanta Consulting Group Advisors LLC bought a new position in Amneal Pharmaceuticals during the first quarter worth about $61,000. nVerses Capital LLC acquired a new position in Amneal Pharmaceuticals in the second quarter valued at about $62,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals during the first quarter worth about $65,000. Institutional investors own 31.82% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Stories
- Five stocks we like better than Amneal Pharmaceuticals
- Investing in Travel Stocks Benefits
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Stock Dividend Cuts Happen Are You Ready?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.